Literature DB >> 29665381

A Refined Developability Classification System.

Julian Rosenberger1, James Butler2, Jennifer Dressman3.   

Abstract

In 2010, the Developability Classification System (DCS) was proposed. The DCS was designed to close the gap between the biopharmaceutics classification system, which is aimed at guiding regulatory decisions about well-characterized drugs, and the need for early evaluation of drug candidates with respect to their suitability for oral delivery. The DCS applied solubility in fasted state simulated intestinal fluid to estimate intestinal solubility, assessed the compensatory nature of permeability and solubility during oral absorption and provided a way of estimating the critical the particle size at which dissolution becomes rate-limiting to absorption. Building on this framework, a refined developability classification system (rDCS) is now proposed. The rDCS is stratified into standard investigations applied to all candidates, and customized investigations. Standard investigation of solubility and permeability can be performed according to in-house methods, and the results compared with standard data sets of fasted state human intestinal fluid solubility and human effective jejunal permeability, which have been generated specifically for rDCS. Customized investigations are triggered when there is potential for supersaturation/precipitation (weak bases; salts of weak acids) and to assess dissolution versus permeation limited absorption. In addition, the rDCS offers facile visualization of the results, enabling pragmatic comparison of drug candidates and formulation approaches.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  Biopharmaceutics Classification System (BCS); dissolution; formulation; high throughput technology(s); in vitro model(s); oral absorption; permeation enhancers(s); solubility; supersaturation

Mesh:

Substances:

Year:  2018        PMID: 29665381     DOI: 10.1016/j.xphs.2018.03.030

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  8 in total

1.  Identification, preclinical profile, and clinical proof of concept of an orally bioavailable pro-drug of miridesap.

Authors:  Duncan Richards; Mark Bamford; Lia Liefaard; Nazneen Haque; Gareth Lewis; Jim Storey; Disala Fernando; Subramanya Kumar; Douglas Thompson; Duncan S Holmes
Journal:  Br J Pharmacol       Date:  2020-02-11       Impact factor: 8.739

2.  "Development of Fixed Dose Combination Products" Workshop Report: Considerations of Gastrointestinal Physiology and Overall Development Strategy.

Authors:  Bart Hens; Maura Corsetti; Marival Bermejo; Raimar Löbenberg; Pablo M González; Amitava Mitra; Divyakant Desai; Dakshina Murthy Chilukuri; Alexis Aceituno
Journal:  AAPS J       Date:  2019-06-06       Impact factor: 4.009

3.  GSK2556286 Is a Novel Antitubercular Drug Candidate Effective In Vivo with the Potential To Shorten Tuberculosis Treatment.

Authors:  Eric L Nuermberger; Maria Santos Martínez-Martínez; Olalla Sanz; Beatriz Urones; Jorge Esquivias; Heena Soni; Rokeya Tasneen; Sandeep Tyagi; Si-Yang Li; Paul J Converse; Helena I Boshoff; Gregory T Robertson; Gurdyal S Besra; Katherine A Abrahams; Anna M Upton; Khisimuzi Mdluli; Gary W Boyle; Sam Turner; Nader Fotouhi; Nicholas C Cammack; Juan Miguel Siles; Marta Alonso; Jaime Escribano; Joel Lelievre; Joaquin Rullas-Trincado; Esther Pérez-Herrán; Robert H Bates; Gareth Maher-Edwards; David Barros; Lluís Ballell; Elena Jiménez
Journal:  Antimicrob Agents Chemother       Date:  2022-05-24       Impact factor: 5.938

4.  Fasted intestinal solubility limits and distributions applied to the biopharmaceutics and developability classification systems.

Authors:  Qamar Abuhassan; Ibrahim Khadra; Kate Pyper; Patrick Augustijns; Joachim Brouwers; Gavin W Halbert
Journal:  Eur J Pharm Biopharm       Date:  2021-12-16       Impact factor: 5.571

5.  Small scale in vitro method to determine a bioequivalent equilibrium solubility range for fasted human intestinal fluid.

Authors:  Qamar Abuhassan; Ibrahim Khadra; Kate Pyper; Gavin W Halbert
Journal:  Eur J Pharm Biopharm       Date:  2021-08-20       Impact factor: 5.571

6.  Non-Effective Improvement of Absorption for Some Nanoparticle Formulations Explained by Permeability under Non-Sink Conditions.

Authors:  Kazuya Sugita; Noriyuki Takata; Etsuo Yonemochi
Journal:  Pharmaceutics       Date:  2022-04-07       Impact factor: 6.525

7.  An in vitro toolbox to accelerate anti-malarial drug discovery and development.

Authors:  Susan A Charman; Alice Andreu; Helena Barker; Scott Blundell; Anna Campbell; Michael Campbell; Gong Chen; Francis C K Chiu; Elly Crighton; Kasiram Katneni; Julia Morizzi; Rahul Patil; Thao Pham; Eileen Ryan; Jessica Saunders; David M Shackleford; Karen L White; Lisa Almond; Maurice Dickins; Dennis A Smith; Joerg J Moehrle; Jeremy N Burrows; Nada Abla
Journal:  Malar J       Date:  2020-01-02       Impact factor: 2.979

8.  Dose-Dependent Solubility-Permeability Interplay for Poorly Soluble Drugs under Non-Sink Conditions.

Authors:  Kazuya Sugita; Noriyuki Takata; Etsuo Yonemochi
Journal:  Pharmaceutics       Date:  2021-03-02       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.